Johnson Johnson Aktie

136,14 EUR +0,64 EUR +0,47 %

20:35:49

FSE

148,53 USD -1,42 USD -0,95 %

20:49:19

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.327,43 Mrd. EUR

KGV24,98Div. Rendite3,40%

WKN853260

ISINUS4781601046

SymbolJNJ

Johnson Johnson Aktien News

Sortieren:Datum Meistgelesen

08.04.25PR NewswireJohnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)

04.04.25PR NewswireTREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arth...

26.03.25PR NewswireRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer

WerbungJohnson Johnson-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

26.03.25PR NewswireNew nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)

20.03.25PR NewswireU.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Croh...

20.03.25PR NewswireRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025

18.03.25PR NewswireNipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now rec...

10.03.25PR NewswireHealth Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

10.03.25PR NewswireIcotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients

08.03.25PR NewswireIcotrokinra results show potential to set a new standard of treatment in plaque psoriasis

21.02.25PR NewswireTREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis

13.02.25PR NewswireNew nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases

28.01.25PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ

23.01.25PR NewswireJohnson & Johnson champions first-ever Canadian consensus paper identifying critical gaps in psoriasis care for patients with skin of colour

23.01.25PR NewswireFindings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology

21.01.25PR NewswireSPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression

16.01.25PR NewswireRYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer

15.01.25PR NewswireNew Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer

09.01.25PR NewswireNipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis

08.01.25PR NewswireJohnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease

07.01.25PR NewswireRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib

10.12.24PR NewswireCARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study

09.12.24PR NewswireWarm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options

09.12.24PR NewswireDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly di...

08.12.24PR NewswireTECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma

08.12.24PR NewswireDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma

27.11.24Korea TimesBlackstone acquires Korean industrial cutting tools maker JJ Tools

22.11.24PR NewswireJohnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor

21.11.24PR NewswireHealth Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

19.11.24PR NewswireJohnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting

18.11.24PR NewswireIcotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

14.11.24PR NewswireNipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study

11.11.24PR NewswireNipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease

08.11.24PR NewswireJohnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma

07.11.24PR NewswireJohnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024

28.10.24PR NewswireTREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease

25.10.24PR NewswireNew SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis

24.10.24PR NewswireJohnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress

15.10.24PR NewswireNipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

10.10.24PR NewswireTREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis

Johnson Johnson News

Johnson Johnson News: auf dieser Seite finden Sie alle Johnson Johnson News und Nachrichten zur Johnson Johnson Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Johnson Johnson News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Johnson Johnson News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.